1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Diakron Pharmaceuticals, Inc. - Product Pipeline Review - 2013

Diakron Pharmaceuticals, Inc. - Product Pipeline Review - 2013

  • December 2013
  • -
  • Global Markets Direct
  • -
  • 24 pages

Diakron Pharmaceuticals, Inc. - Product Pipeline Review - 2013

Summary

Global Market Direct’s pharmaceuticals report, “Diakron Pharmaceuticals, Inc. - Product Pipeline Review - 2013” provides data on the Diakron Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Diakron Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Diakron Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Diakron Pharmaceuticals, Inc. - Brief Diakron Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Diakron Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Diakron Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Diakron Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Diakron Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Diakron Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Diakron Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Diakron Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Diakron Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Table Of Contents

Diakron Pharmaceuticals, Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Diakron Pharmaceuticals, Inc. Snapshot 4
Diakron Pharmaceuticals, Inc. Overview 4
Key Information 4
Key Facts 4
Diakron Pharmaceuticals, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Diakron Pharmaceuticals, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Diakron Pharmaceuticals, Inc. - Pipeline Products Glance 9
Diakron Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 9
Phase I Products/Combination Treatment Modalities 9
Diakron Pharmaceuticals, Inc. - Early Stage Pipeline Products 10
Preclinical Products/Combination Treatment Modalities 10
Discovery Products/Combination Treatment Modalities 11
Diakron Pharmaceuticals, Inc. - Drug Profiles 12
DP-4088 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
DP-3005 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
Drug For Diabetes 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
Diakron Pharmaceuticals, Inc. - Pipeline Analysis 16
Diakron Pharmaceuticals, Inc. - Pipeline Products by Therapeutic Class 16
Diakron Pharmaceuticals, Inc. - Pipeline Products by Target 18
Diakron Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 19
Diakron Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 20
Diakron Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 21
Diakron Pharmaceuticals, Inc. - Locations And Subsidiaries 22
Head Office 22
Appendix 23
Methodology 23
Coverage 23
Secondary Research 23
Primary Research 23
Expert Panel Validation 23
Contact Us 24
Disclaimer 24



List of Tables

Diakron Pharmaceuticals, Inc., Key Information 4
Diakron Pharmaceuticals, Inc., Key Facts 4
Diakron Pharmaceuticals, Inc. - Pipeline by Indication, 2013 6
Diakron Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 7
Diakron Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 8
Diakron Pharmaceuticals, Inc. - Phase I, 2013 9
Diakron Pharmaceuticals, Inc. - Preclinical, 2013 10
Diakron Pharmaceuticals, Inc. - Discovery, 2013 11
Diakron Pharmaceuticals, Inc. - Pipeline by Therapeutic Class, 2013 17
Diakron Pharmaceuticals, Inc. - Pipeline by Target, 2013 18
Diakron Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2013 19
Diakron Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2013 20
Diakron Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2013 21



List of Figures

Diakron Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2013 6
Diakron Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 7
Diakron Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 8
Diakron Pharmaceuticals, Inc. - Pipeline by Top 10 Therapeutic Class, 2013 16
Diakron Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2013 18
Diakron Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2013 21



Companies Mentioned

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.